Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1-3 prior therapies: phase 2 study interim analysis (IA)
Robert Orlowski,Sosana Delimpasi,Jan Straub,Argiris Symeonidis,Ludek Pour,Roman Hajek,Cyrille Touzeau, Viralkumar Bhanderi,Petr Pavlicek,Pawel Robak,Jesus G. Berdeja,Jeffrey V. Matous,Lionel Karlin,Sonja Zweegman,Sebastian Grosicki,Andrzej Pluta,Suman Kambhampati,Kaveri Suryanarayan,Philip Twumasi-Ankrah,Ajeeta Dash,Richard Labotka,Meletios-Athanasios Dimopoulos CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2021）
AI 理解论文
溯源树
样例
